All Articles
- FDA Approves Ziextenzo, Third Biosimilar to Pegfilgrastim for Febrile Neutropenia
- Trump Will Nominate Dr Hahn as Next FDA Commissioner
- Researchers Report High Rates of E-Cigarette Use Among Children and Teens
Financial Toxicity, Genomic Testing, Leukemia, Head & Neck Cancers , In the Literature, Genetics & Genomics
- Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
- Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda Advanced Head and Neck Cancers
- Discussing Costs of Genomic Testing with Patients
- Zejula Now Approved for Late-Line Ovarian Cancer
- Trump Set to Nominate Hahn as FDA Commissioner
- FDA Aims to Improve Breast Implant Guidance
Breast Cancer, FDA Approvals, News & Updates, Multiple Myeloma, Pediatric Cancers, In the Literature
The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer. Read More ›
FDA Approvals, News & Updates, National Comprehensive Cancer Network (NCCN), NCCN Guideline Updates, In the Literature
FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines. Read More ›
Although our top priority is to provide high-quality care, we often encounter barriers and hurdles that can affect where, when, and how we interact with our patients and staff. Given the increased focus on the acquisition, handling, preparation, and administration of drugs in medical practices—especially oncology practices—we are now being challenged with existing and emerging restrictions and expectations, which are continually in a state of transition. In this article, I want to share 3 important tips that will help you be more prepared and protected this fall. Read More ›
People who are less engaged in their own medical care have more negative health consequences, including higher readmission rates, poor care coordination, and less confidence. It is therefore imperative to keep patients engaged in their own healthcare, and current technology plays an important role in achieving this goal, according to Sangeeta Agarawal, RN, CAS, MS, Founder and Chief Executive Officer, Helpsy Health, San Francisco, CA. Read More ›
By Wayne Kuznar
BLU-667, a novel inhibitor of RET, elicited responses in more than 50% of patients with RET fusion–positive advanced non–small-cell lung cancer (NSCLC), according to data from an ongoing phase 1 clinical trial presented at ASCO 2019. Read More ›
By Wayne Kuznar
Tumor-specific antigens provide personalized targets for immunotherapy. Neoantigen vaccines are a new type of immunotherapy that can elicit immune response and achieve remission. Evidence is compelling to support neoantigens as the target of effective immune responses against cancer and to support an association between neoantigen load with improved clinical outcome, said Patrick Alexander Ott, MD, PhD, Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, at ASCO 2019. Read More ›
By Wayne Kuznar
High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis. At the 2019 American Society of Clinical Oncology Annual Meeting, results from a clinical trial showed that treatment with ONC201, a unique, small molecule DRD2 antagonist, resulted in durable tumor regression in adults with recurrent high-grade H3 K27M-mutant gliomas. Read More ›